論文

査読有り 責任著者 国際誌
2016年9月

A convenient and effective strategy for the enrichment of tumor-initiating cell properties in prostate cancer cells.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • Yiming Zhang
  • ,
  • Yiqiang Huang
  • ,
  • Zhong Jin
  • ,
  • Xiezhao Li
  • ,
  • Bingkun Li
  • ,
  • Peng Xu
  • ,
  • Peng Huang
  • ,
  • Chunxiao Liu

37
9
開始ページ
11973
終了ページ
11981
記述言語
英語
掲載種別

Stem-like prostate cancer (PrCa) cells, also called PrCa stem cells (PrCSCs) or PrCa tumor-initiating cells (PrTICs), are considered to be involved in the mediation of tumor metastasis and may be responsible for the poor prognosis of PrCa patients. Currently, the methods for PrTIC sorting are mainly based on cell surface marker or side population (SP). However, the rarity of these sorted cells limits the investigation of the molecular mechanisms and therapeutic strategies targeting PrTICs. For PrTIC enrichment, we induced cancer stem cell (CSC) properties in PrCa cells by transducing three defined factors (OCT3/4, SOX2, and KLF4), followed by culture with conventional serum-containing medium. The CSC properties in the transduced cells were evaluated by proliferation, cell cycle, SP assay, drug sensitivity technology, in vivo tumorigenicity, and molecular marker analysis of PrCSCs compared with parental cells and spheroids. After culture with serum-containing medium for 8 days, the PrCa cells transduced with the three factors showed significantly enhanced CSC properties in terms of marker gene expression, sphere formation, chemoresistance to docetaxel, and tumorigenicity. The percentage of CD133+/CD44+ cells was ninefold higher in the transduced cell population than in the adherent PC3 cell population (2.25 ± 0.62 vs. 0.25 ± 0.12 %, respectively), and the SP increased to 1.22 ± 0.18 % in the transduced cell population, but was undetectable in the adherent population. This method can be used to obtain abundant PrTIC material and enables a complete understanding of PrTIC biology and development of novel therapeutic agents targeting PrTICs.

リンク情報
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/27113741
ID情報
  • eISSN : 1423-0380
  • PubMed ID : 27113741

エクスポート
BibTeX RIS